1 Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, et al. The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis. 2008;12(9):987–93.
2 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
3 Zaugg M, Salfinger M, Opravil M, Lüthy R. Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review. Clin Infect Dis. 1993;16(4):540–9.
4 Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–64.
5 Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–34.
6 Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905–13.
7 Heurlin N, Petrini B. Treatment of non-tuberculous mycobacterial infections in patients without AIDS. Scand J Infect Dis. 1993;25(5):619–23.
8 Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J. 2003;21(3):478–82.